» Authors » Michele Sorgenfrei

Michele Sorgenfrei

Explore the profile of Michele Sorgenfrei including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 116
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Hanswillemenke A, Hofacker D, Sorgenfrei M, Fruhner C, Franz-Wachtel M, Schwarzer D, et al.
Nat Chem Biol . 2024 Jan; 20(5):555-565. PMID: 38233583
Drug-ID is a novel method applying proximity biotinylation to identify drug-protein interactions inside living cells. The covalent conjugation of a drug with a biotin ligase enables targeted biotinylation and identification...
2.
Botsch J, Junker R, Sorgenfrei M, Ogger P, Stier L, von Gronau S, et al.
Nat Commun . 2024 Jan; 15(1):410. PMID: 38195637
Transmembrane E3 ligases play crucial roles in homeostasis. Much protein and organelle quality control, and metabolic regulation, are determined by ER-resident MARCH6 E3 ligases, including Doa10 in yeast. Here, we...
3.
Critcher M, Gruijs da Silva L, Dormann D, Campbell Z, Le T, Rocchi P, et al.
Trends Biochem Sci . 2023 Jan; 48(2):97-99. PMID: 36669467
No abstract available.
4.
Sorgenfrei M, Hurlimann L, Remy M, Keller P, Seeger M
Trends Biochem Sci . 2022 Apr; 47(8):673-688. PMID: 35487808
Rapid phenotypic antimicrobial susceptibility testing (AST) requires the enrichment of live bacteria from patient samples, which is particularly challenging in the context of life-threatening bloodstream infections (BSIs) due to low...
5.
Walter J, Scherer M, Hutter C, Garaeva A, Zimmermann I, Wyss M, et al.
EMBO Rep . 2022 Mar; 23(4):e54199. PMID: 35253970
The ongoing COVID-19 pandemic represents an unprecedented global health crisis. Here, we report the identification of a synthetic nanobody (sybody) pair, Sb#15 and Sb#68, that can bind simultaneously to the...
6.
Custodio T, Das H, Sheward D, Hanke L, Pazicky S, Pieprzyk J, et al.
Nat Commun . 2020 Nov; 11(1):5588. PMID: 33149112
The coronavirus SARS-CoV-2 is the cause of the ongoing COVID-19 pandemic. Therapeutic neutralizing antibodies constitute a key short-to-medium term approach to tackle COVID-19. However, traditional antibody production is hampered by...